|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115271 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-24 11:42:55 |
|
注册时间: Date of Registration: |
2025-12-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于多模态超声融合与可解释人工智能的甲状腺乳头状癌淋巴结转移机制研究 |
|
Public title: |
Mechanistic Study of Lymph Node Metastasis in Papillary Thyroid Carcinoma Based on Multimodal Ultrasound Fusion and Explainable Artificial Intelligence |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于多模态超声融合与可解释人工智能的甲状腺乳头状癌淋巴结转移机制研究 |
|
Scientific title: |
Mechanistic Study of Lymph Node Metastasis in Papillary Thyroid Carcinoma Based on Multimodal Ultrasound Fusion and Explainable Artificial Intelligence |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈雨凡 |
研究负责人: |
陈雨凡 |
|
Applicant: |
Chen Yufan |
Study leader: |
Chen Yufan |
|
申请注册联系人电话: Applicant telephone: |
+86 188 8888 8888 |
研究负责人电话: Study leader's telephone: |
+86 20 89168133 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
893829761@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
893829761@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市海珠区新港中路466号 |
研究负责人通讯地址: |
广东省广州市海珠区新港中路466号 |
|
Applicant address: |
No. 466, Xingang Middle Road, Haizhu District, Guangzhou,Guangdong |
Study leader's address: |
No. 466, Xingang Middle Road, Haizhu District, Guangzhou,Guangdong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广东省第二人民医院 |
||
|
Applicant's institution: |
Guangdong Second Provincial General Hospital |
||
|
研究负责人所在单位: |
广东省第二人民医院(广东省卫生应急医院) |
||
|
Affiliation of the Leader: |
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital) |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-KY-KZ-507-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广东省第二人民医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Guangdong Second Provincial General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-27 00:00:00 |
||
|
伦理委员会联系人: |
胡楚璇 |
||
|
Contact Name of the ethic committee: |
Hu Chuxuan |
||
|
伦理委员会联系地址: |
广东省广州市海珠区新港中路466号 |
||
|
Contact Address of the ethic committee: |
No. 466, Xingang Middle Road, Haizhu District, Guangzhou,Guangdong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 89169186 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
Hchuxuan@126.com |
|
研究实施负责(组长)单位: |
广东省第二人民医院(广东省卫生应急医院) |
||||||||||||||||||||||
|
Primary sponsor: |
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市海珠区新港中路466号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 466, Xingang Middle Road, Haizhu District, Guangzhou,Guangdong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2025博士后工作站 |
||||||||||||||||||||||
|
Source(s) of funding: |
Postdoctoral Research Station (2025) |
||||||||||||||||||||||
|
Target disease: |
Papillary Thyroid Carcinoma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
甲状腺乳头状癌(PTC)颈部淋巴结转移(LNM)风险评估仍缺乏安全、精准的预测手段,是导致PTC过度治疗的重要原因。针对PTC患者LNM风险评估难和人工智能模型可解释性不足两大问题,本研究拟基于常规临床检查阶段的超声检查数据,构建一个融合临床信息与多模态超声图像的可解释性人工智能模型,以实现对PTC患者LNM风险的无创精准预测,为个体化治疗提供决策支持。 |
||||||||||||||||||||||
|
Objectives of Study: |
Accurate preoperative assessment of cervical lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) remains challenging and is a major cause of overtreatment. To address the limitations of current LNM risk evaluation and the low interpretability of artificial intelligence (AI) models, this study proposes an explainable AI framework integrating clinical data and multimodal ultrasound imaging acquired during routine examinations. The model aims to achieve non-invasive and precise prediction of LNM risk in PTC patients, providing a reliable basis for individualized clinical decision-making. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①年龄均在18岁及以上;②患者均接受甲状腺切除术及淋巴结清扫术,并有对应的病理结果;③术前均进行甲状腺结节的超声检查。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age >=18 years;2.Underwent thyroidectomy with lymph node dissection, with corresponding histopathologic confirmation;3.Underwent preoperative ultrasonography for evaluation of thyroid nodules. |
||||||||||||||||||||||
|
排除标准: |
1.颈部外伤史;2.术前接受过PTC的相关治疗;3.术前超声图像质量不佳;4.资料不完整的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.History of cervical trauma; 2.Prior therapy for papillary thyroid carcinoma before surgery; 3.Poor-quality preoperative ultrasound images; 4.Incomplete clinical or imaging data; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-15 00:00:00至 To 2027-06-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-12-30 00:00:00 至 To 2027-06-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集与管理由病例报告表(CRF)和电子数据采集系统(EDC)组成。所有临床资料、实验室指标及术前多模态超声图像均按照统一CRF格式记录,并通过医院电子病历系统和影像归档系统(PACS)导入。数据管理由专人负责,所有数据存储于受控服务器,按研究方案定期核对、备份并进行质量控制,确保数据的准确性与完整性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and management consist of a standardized Case Record Form (CRF) and an Electronic Data Capture (EDC) system. Clinical variables, laboratory results, and multimodal ultrasound images are recorded according to the predefined CRF and imported from the hospital EMR and PACS systems. All data are stored on secured servers with access control, routine quality checks, and regular backups to ensure data accuracy, completeness, and integrity. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |